<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="abstract"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Eur Psychiatry</journal-id><journal-id journal-id-type="iso-abbrev">Eur Psychiatry</journal-id><journal-id journal-id-type="publisher-id">EPA</journal-id><journal-title-group><journal-title>European Psychiatry</journal-title></journal-title-group><issn pub-type="ppub">0924-9338</issn><issn pub-type="epub">1778-3585</issn><publisher><publisher-name>Cambridge University Press</publisher-name><publisher-loc>Cambridge, UK</publisher-loc></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmc">PMC11861947</article-id><article-id pub-id-type="doi">10.1192/j.eurpsy.2024.1452</article-id><article-id pub-id-type="other">EPV0830</article-id><article-id pub-id-type="pii">S0924933824014524</article-id><article-categories><subj-group subj-group-type="heading"><subject>Abstract</subject></subj-group><subj-group subj-group-type="section"><subject>e-Poster Viewing</subject></subj-group></article-categories><title-group><article-title>Asenapine versus other atycipal antipsychotics for schizoaffective disorder Case study</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Shaska</surname><given-names>E.</given-names></name><xref rid="aff3191" ref-type="aff"/></contrib></contrib-group><aff id="aff3191">Acute Services, <institution>Psychiatric Hospital</institution>, <city>Vlora</city>, <country>Albania</country></aff><pub-date publication-format="electronic" date-type="collection" iso-8601-date="2024-04"><month>4</month><year>2024</year></pub-date><pub-date pub-type="epub"><day>27</day><month>8</month><year>2024</year></pub-date><volume>67</volume><issue seq="1427">Suppl 1</issue><issue-title content-type="special_issue">Abstracts of the 32nd European Congress of Psychiatry</issue-title><fpage>S698</fpage><lpage>S698</lpage><permissions><copyright-statement>&#x000a9; The Author(s) 2024</copyright-statement><copyright-year>2024</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article, distributed under the terms of the Creative Commons Attribution licence (<uri xlink:href="https://creativecommons.org/licenses/by/4.0/">https://creativecommons.org/licenses/by/4.0/</uri>), which permits unrestricted re-use, distribution, and reproduction in any medium, provided the original work is properly cited.</license-p></license></permissions><self-uri xlink:title="pdf" xlink:href="S0924933824014524a.pdf"/><abstract><sec id="sec7826"><title>Introduction</title><p>Antipsychotics are psyschotropic medications that are&#x000a0;indicated for the treatment of physchosis and mood disorders. Due to minimal side effects and their efficacy (affecting many receptors) compared to standard antipsychotics, today atypical antipsychotics are being used more and more as first-line treatment.</p><p>The aim of this study is to show the efficacy of asenapine and its tolerability as opposed to other atypical antipsychotics.</p></sec><sec id="sec7827"><title>Objectives</title><p>
<list list-type="order"><list-item><p>What are the side effects identified?</p></list-item><list-item><p>Side effects and efficacy of asenapine vs other atypical antipsychotics?
</p></list-item></list></p></sec><sec id="sec7828"><title>Methods</title><p>
It is a comparative, regular, clinical study,&#x000a0;an examination case of a 53-year old female diagnosed with Schizoaffective Disorder 27 years ago and treated outside of hospital with atypical antipsychotics, such as: risperidone, olanzapine, quetiapine, aripiprazole, amisulpride. The study covers the timespan of 2010-2022.</p></sec><sec id="sec7829"><title>Results</title><p>The results showed that asenapine sublingual 15 mg had fewer side effects than other atypical antipsychotics. They were mouth dryness, headache, fatigue.</p><p>The other atypical antipsychotics caused: metabolic disorders, like considerable weight gain, cholesterol and glycaemia increase, extrapyramidal side effects, hyperprolactinemia.</p><p>Asenapine sublingual 15 mg was not as effective in treating Schyzoaffective Disorder as risperdal 5mg, olanzapine 15 mg, aripiprazole 20 mg, amisulpride 600 mg.</p><p>The efficacy of&#x000a0;asenapine sublingual 15mg was the same as quetiapine 400 mg.</p></sec><sec id="sec7830"><title>Conclusions</title><p>This study showed that asenapine has minimal side effects but its efficacy in treating Schyzoaffective Disorder as monotherapy is lower than other atypical antipsychotics.</p></sec><sec id="sec7831"><title>Key words</title><p>antipsychotics, schyzoaffective disorder, side effects, efficacy</p></sec><sec id="sec7832"><title>Disclosure of Interest</title><p>None Declared</p></sec></abstract><counts><page-count count="1"/></counts></article-meta></front></article>